Roche to acquire PathAI for AI-driven digital pathology

Roche entered into a definitive merger agreement to acquire PathAI, a US-based digital pathology and AI-powered technology company. The acquisition is expected to close in the second half of 2026.

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens.”roche.com

• 1 source
• roche.comRoche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnosticsMay 7, 2026

Summarized from public sources; check the original articles before acting on it.